Petros Pharmaceuticals Q4 EPS $(2.17) Misses $(1.11) Estimate, Sales $364.25K Miss $1.55M Estimate
Petros Pharmaceuticals Q4 EPS $(2.17) Misses $(1.11) Estimate, Sales $364.25K Miss $1.55M Estimate
Petros Pharmicals第四季度每股收益美元（2.17美元）未達到預期（1.11美元），銷售額爲364.25萬美元，低於155萬美元的預期
Petros Pharmaceuticals (NASDAQ:PTPI) reported quarterly losses of $(2.17) per share which missed the analyst consensus estimate of $(1.11) by 95.5 percent. This is a 6.9 percent decrease over losses of $(2.03) per share from the same period last year. The company reported quarterly sales of $364.25 thousand which missed the analyst consensus estimate of $1.55 million by 76.50 percent. This is a 54.36 percent decrease over sales of $798.10 thousand the same period last year.
彼得羅斯製藥公司（納斯達克股票代碼：PTPI）公佈的季度虧損爲每股2.17美元，比分析師普遍預期的1.11美元（1.11美元）低95.5％。與去年同期每股虧損2.03美元（2.03）相比，下降了6.9％。該公司公佈的季度銷售額爲364,250美元，比分析師普遍預期的155萬美元低76.50％。這比去年同期的798,100美元的銷售額下降了54.36％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。